Literature DB >> 3140993

Human liver morphine UDP-glucuronyl transferase enantioselectivity and inhibition by opioid congeners and oxazepam.

A Wahlström1, G M Pacifici, B Lindström, L Hammar, A Rane.   

Abstract

1. Morphine uridine diphosphate glucuronyl transferase (UDP-GT) was studied in human liver microsomes. The (-)- and (+)-morphine enantiomers were used as substrates and inhibitors, such as oxazepam and various opioid congeners were employed to characterize the different glucuronidation pathways. The kinetics of the oxazepam inhibition were studied in the rat liver. 2. The overall glucuronidation of (+)-morphine was higher than that of (-)-morphine. The morphine congeners tested, potently inhibited the formation of (-)-morphine-3-glucuronide ((-)-M3G), except for normorphine and codeine. The formation of (+)-morphine-6-glucuronide [+)-M6G) was potently inhibited by only dextromethorphan and (+)-naloxone. All drugs except normorphine inhibited the formation of (+)-M3G by 18-50%. 3. The metabolism of (-)-morphine to (-)-M3G was more sensitive to oxazepam inhibition than the formation of (+)-M3G from (+)-morphine in the rat liver. 4. The glucuronidation of natural morphine is subject to in vitro interaction with oxazepam and several opiate drugs. Our study supports the theory of more than one type of UDP-GT being involved in morphine glucuronidation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3140993      PMCID: PMC1854048          DOI: 10.1111/j.1476-5381.1988.tb11598.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  9 in total

1.  Structural requirements in the reaction of morphine uridine diphosphate glucuronyltransferase with opioid substances.

Authors:  E Sanchez; E Del Villar; T R Tephly
Journal:  Biochem J       Date:  1978-01-01       Impact factor: 3.857

2.  Suppression of the drug-induced morphine withdrawal syndrome by cyproheptadine.

Authors:  K Opitz; I Reimann
Journal:  Psychopharmacologia       Date:  1973-01-01

3.  Pharmacological treatment of cancer pain with special reference to the oral use of morphine.

Authors:  A Rane; J Säwe; B Dahlström; L Paalzow; L Kager
Journal:  Acta Anaesthesiol Scand Suppl       Date:  1982

4.  Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation.

Authors:  J Säwe; L Kager; J O Svensson Eng; A Rane
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

5.  Determination of morphine, morphine-3-glucuronide and (tentatively) morphine-6-glucuronide in plasma and urine using ion-pair high-performance liquid chromatography.

Authors:  J O Svensson; A Rane; J Säwe; F Sjöqvist
Journal:  J Chromatogr       Date:  1982-07-09

6.  Human metabolism of cyproheptadine.

Authors:  C C Porter; B H Arison; V F Gruber; D C Titus; W J Vandenheuvel
Journal:  Drug Metab Dispos       Date:  1975 May-Jun       Impact factor: 3.922

7.  Inhibition of morphine glucuronidation by oxazepam in human fetal liver microsomes.

Authors:  G M Pacifici; A Rane
Journal:  Drug Metab Dispos       Date:  1981 Nov-Dec       Impact factor: 3.922

8.  Natural (-)- and unnatural (+)-enantiomers of morphine: comparative metabolism and effect of morphine and phenobarbital treatment.

Authors:  A Rane; B Gawronska-Szklarz; J O Svensson
Journal:  J Pharmacol Exp Ther       Date:  1985-09       Impact factor: 4.030

9.  Metabolic interaction between morphine and various benzodiazepines.

Authors:  G M Pacifici; L L Gustafsson; J Säwe; A Rane
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1986-04
  9 in total
  7 in total

Review 1.  Drug interactions with patient-controlled analgesia.

Authors:  Jorn Lotsch; Carsten Skarke; Irmgard Tegeder; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Dextromethorphan differentially affects opioid antinociception in rats.

Authors:  Shiou-Lan Chen; Eagle Yi-Kung Huang; Lok-Hi Chow; Pao-Luh Tao
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

Review 3.  Morphine-6-glucuronide: an analgesic of the future?

Authors:  J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Population pharmacokinetics of heroin and its major metabolites.

Authors:  Elisabeth J Rook; Alwin D R Huitema; Wim van den Brink; Jan M van Ree; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids.

Authors:  Glynn A Morrish; David J R Foster; Andrew A Somogyi
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

Review 6.  Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors.

Authors:  H K Kroemer; U Klotz
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

7.  Characterisation of the metabolites of 1,8-cineole transferred into human milk: concentrations and ratio of enantiomers.

Authors:  Frauke Kirsch; Andrea Buettner
Journal:  Metabolites       Date:  2013-01-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.